Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
The lancet. Diabetes & endocrinology · 2026 Oct 30 · Yokote K, Yamauchi T, Shingaki T et
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 29 20:00 ETSource: The lancet. Diabetes & endocrinology
From the source
Read at pubmed.ncbi.nlm.nih.govEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
The lancet. Diabetes & endocrinology · 2026 Oct 30 · Yokote K, Yamauchi T, Shingaki T et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42962687/
